Kardigan targets IPO to support cardiology pipeline progression

Just nether a twelvemonth and a fractional aft its debut, Kardigan is eyeing a listing connected the Nasdaq to enactment the continued improvement of its in-licensed cardiology pipeline – adding different sanction to the burgeoning database of American biotechs undertaking IPOs this year.

The ARCH Venture Partners-backed institution volition commercialized nether the ticker “KARD.” While Kardigan has not yet revealed the fig oregon terms of shares it volition offer, it did picture wherever the funds volition beryllium used. Primarily, proceeds volition assistance advancement 3 of the biotech’s pipeline cardiovascular therapies done the clinic.

Kardigan’s assets see danicamtiv, a MyoKardia and Bristol Myers Squibb (BMS)-licensed campaigner to dainty familial dilated cardiomyopathy (DCM) – a illness characterised by the heart’s conflict to efficaciously pump humor astir the body. The nonstop myosin activator is presently nether valuation successful a Phase IIb/III proceedings wrong the condition. If approved, it could go the archetypal therapy to scope the DCM market.

Alongside danicamtiv improvement efforts, Kardigan plans todirect funds to its different BMS-MyoKardia-licensed therapy, ataciguat, which is presently successful mid-stage objective trials for the attraction of mean calcific aortic valve stenosis.

On apical of these programmes, Kardigan plans to propulsion its precocious humor pressure-targeting antisense oligonucleotide, tonlamarsen, further on objective development. The cause is presently successful a Phase IIb trial, which is looking astatine its imaginable successful patients with acute, terrible cases of the condition.

Kardigan volition usage immoderate leftover currency to buy, in-license oregon put successful assets, businesses, technologies oregon products related to its halfway focus.

Kardigan’s IPO plans travel a small aft the institution raised $254m successful an ARCH-backed Series B financing circular backmost successful October 2025, which contributed to backing the objective improvement of danicamtiv, ataciguat and tonlamarsen.

US sees biotech IPO surge

As Kardigan files its intent to IPO, it joins the increasing database of biotechs eyeing a spot connected the nationalist marketplace successful 2026, arsenic listing enactment sees a notable uptick year-on-year (YoY).

According to GlobalData’s Pharmaceutical Intelligence Center, the fig of IPOs announced successful Q1 2026 jumped much than 80% compared with the aforesaid play successful 2025.

Notable examples successful 2026 see Eikon Therapeutics’ $381.2m rise successful January, arsenic good arsenic Generate Biomedicines’ $400m rise successful February.

After a flurry of IPOs successful Q1, Q2 has maintained momentum. Kailera Therapeutics made past successful April by securing 1 of the largest IPOs successful the sector’s past valued astatine $625m.